This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

PX-12

Cascadian Therapeutics, Inc.

Drug Names(s): PX-12

Description: PX-12 is designed to inhibit the activity of the protein thioredoxin. Increased thioredoxin levels in cancer cells have been linked to the aggressive proliferation of solid tumors, including colon, lung, and gastric cancers.

Deal Structure: In 2006, Biomira acquired a privately-held biopharmaceutical company, ProIX Pharmaceuticals, and its pipeline, which included PX-12.


PX-12 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug